Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?

por Regan, Meredith M.
Publicado 2022

Accelerating progress to innovation for patients: Trial design and risk stratification()

por Regan, Meredith M.
Publicado 2021

Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy

por Buyse, Marc, Saad, Everardo D, Burzykowski, Tomasz, Regan, Meredith M, Sweeney, Christopher S
Publicado 2022

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal w...

por Regan, Meredith M, Price, Karen N, Giobbie-Hurder, Anita, Thürlimann, Beat, Gelber, Richard D
Publicado 2011

Reply to F. Tomao et al

por Ribi, Karin, Bernhard, Jürg, Luo, Weixiu, Regan, Meredith M., Fleming, Gini F., Francis, Prudence A.
Publicado 2016

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy:...

por Dowsett, Mitch, Sestak, Ivana, Regan, Meredith M., Dodson, Andrew, Viale, Giuseppe, Thürlimann, Beat, Colleoni, Marco, Cuzick, Jack
Publicado 2018

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

por Mantia, Charlene M., Werner, Lillian, Stwalley, Brian, Ritchings, Corey, Tarhini, Ahmad A., Atkins, Michael B., McDermott, David F., Regan, Meredith M.
Publicado 2021

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses

por Xie, Wanling, Halabi, Susan, Tierney, Jayne F, Sydes, Matthew R, Collette, Laurence, Dignam, James J, Buyse, Marc, Sweeney, Christopher J, Regan, Meredith M
Publicado 2019

Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmen...

por Buechler, Steven A, Gray, Kathryn P, Gökmen-Polar, Yesim, Willis, Scooter, Thürlimann, Beat, Kammler, Rosita, Viale, Giuseppe, Leyland-Jones, Brian, Badve, Sunil S, Regan, Meredith M
Publicado 2019

Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial

por Sun, Zhuoxin, Niman, Samuel M., Pagani, Olivia, Partridge, Ann H., Azim, Hatem A., Peccatori, Fedro A., Ruggeri, Monica, Di Leo, Angelo, Colleoni, Marco, Gelber, Richard D., Regan, Meredith M.
Publicado 2020

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group T...

por Kensler, Kevin H., Regan, Meredith M., Heng, Yujing J., Baker, Gabrielle M., Pyle, Michael E., Schnitt, Stuart J., Hazra, Aditi, Kammler, Roswitha, Thürlimann, Beat, Colleoni, Marco, Viale, Giuseppe, Brown, Myles, Tamimi, Rulla M.
Publicado 2019

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

por Pernas, Sonia, Guerriero, Jennifer L., Naumenko, Sergey, Goel, Shom, Regan, Meredith M., Hu, Jiani, Harrison, Beth T., Lynce, Filipa, Lin, Nancy U., Partridge, Ann, Morikawa, Aki, Hutchinson, John, Mittendorf, Elizabeth A., Sokolov, Artem, Overmoyer, Beth
Publicado 2022

Digital Quantification of Gene Expression in Sequential Breast Cancer Biopsies Reveals Activation of an Immune Response

por Jeselsohn, Rinath M., Werner, Lillian, Regan, Meredith M., Fatima, Aquila, Gilmore, Lauren, Collins, Laura C., Beck, Andrew H., Bailey, Shannon T., He, Housheng Hansen, Buchwalter, Gilles, Brown, Myles, Iglehart, J. Dirk, Richardson, Andrea, Come, Steven E.
Publicado 2013

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

por Coates, Alan S, Millar, Ewan KA, O'Toole, Sandra A, Molloy, Timothy J, Viale, Giuseppe, Goldhirsch, Aron, Regan, Meredith M, Gelber, Richard D, Sun, Zhuoxin, Castiglione-Gertsch, Monica, Gusterson, Barry, Musgrove, Elizabeth A, Sutherland, Robert L
Publicado 2012

DNA methylation markers predict recurrence-free interval in triple-negative breast cancer

por Fackler, Mary Jo, Cho, Soonweng, Cope, Leslie, Gabrielson, Edward, Visvanathan, Kala, Wilsbach, Kathleen, Meir-Levi, Danielle, Lynch, Charles F., Marks, Jeffrey, Geradts, Joseph, Regan, Meredith M., Viale, Giuseppe, Wolff, Antonio C., Sukumar, Saraswati, Umbricht, Christopher B.
Publicado 2020

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

por Pagani, Olivia, Francis, Prudence A., Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo, Pinotti, Graziella, Di Leo, Angelo, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Regan, Meredith M.
Publicado 2020

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

por Regan, Meredith M, Mantia, Charlene M, Werner, Lillian, Tarhini, Ahmad A, Larkin, James, Stephen Hodi, F, Wolchok, Jedd, Postow, Michael A, Stwalley, Brian, Moshyk, Andriy, Ritchings, Corey, Re, Sandra, van Dijck, Wim, McDermott, David F, Atkins, Michael B
Publicado 2021

Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer

por Garrido-Castro, Ana C., Regan, Meredith M., Niman, Samuel M., Nakhlis, Faina, Remolano, Claire, Rosenbluth, Jennifer M., Block, Caroline, Warren, Laura E., Bellon, Jennifer R., Yeh, Eren, Harrison, Beth T., Troll, Elizabeth, Lin, Nancy U., Tolaney, Sara M., Overmoyer, Beth, Lynce, Filipa
Publicado 2023

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

por Regan, Meredith M., Werner, Lillian, Rao, Sumati, Gupte-Singh, Komal, Hodi, F. Stephen, Kirkwood, John M., Kluger, Harriet M., Larkin, James, Postow, Michael A., Ritchings, Corey, Sznol, Mario, Tarhini, Ahmad A., Wolchok, Jedd D., Atkins, Michael B., McDermott, David F.
Publicado 2019

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

por Johansson, Harriet, Gray, Kathryn P., Pagani, Olivia, Regan, Meredith M., Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf, Colleoni, Marco, Rabaglio, Manuela, Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A.
Publicado 2016